{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T02:47:04Z","timestamp":1778986024357,"version":"3.51.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000102","name":"Health Resources and Services Administration","doi-asserted-by":"publisher","award":["U3CRH33332"],"award-info":[{"award-number":["U3CRH33332"]}],"id":[{"id":"10.13039\/100000102","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Subst Abuse Treat Prev Policy"],"DOI":"10.1186\/s13011-024-00628-4","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T12:27:21Z","timestamp":1734697641000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Understanding MAT access in the context of unused MAT capacity in the United States: when increasing rural MAT capacity is not enough"],"prefix":"10.1186","volume":"19","author":[{"given":"Carolyn Carpenedo","family":"Mun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Zambrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eileen","family":"Tallman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Bresani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Meyers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,20]]},"reference":[{"key":"628_CR1","doi-asserted-by":"publisher","DOI":"10.15620\/cdc:122556","author":"MR Spencer","year":"2022","unstructured":"Spencer MR, Mini\u00f1o AM, Warner M. Drug overdose deaths in the United States, 2001\u20132021. Hyattsville, MD: National Center for Health Statistics; 2022. https:\/\/doi.org\/10.15620\/cdc:122556. NCHS Data Brief, no 457."},{"key":"628_CR2","unstructured":"Ahmad FB, Cisewski JA, Rossen LM, Sutton P. Provisional drug overdose death counts. National Center for Health Statistics; 2023. https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm"},{"issue":"2","key":"628_CR3","doi-asserted-by":"publisher","first-page":"e1920622","DOI":"10.1001\/jamanetworkopen.2019.20622","volume":"3","author":"SE Wakeman","year":"2020","unstructured":"Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, Azocar F, Sanghavi DM. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020;3(2):e1920622. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.20622.","journal-title":"JAMA Netw Open"},{"key":"628_CR4","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","volume":"357","author":"L Sordo","year":"2017","unstructured":"Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, Ferri M, Pastor-Barriuso R. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ (Clinical Res Ed). 2017;357:j1550. https:\/\/doi.org\/10.1136\/bmj.j1550.","journal-title":"BMJ (Clinical Res Ed)"},{"issue":"9","key":"628_CR5","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","volume":"78","author":"T Santo Jr","year":"2021","unstructured":"Santo T Jr, Clark B, Hickman M, Grebely J, Campbell G, Sordo L, Chen A, Tran LT, Bharat C, Padmanathan P, Cousins G, Dupouy J, Kelty E, Muga R, Nosyk B, Min J, Pavarin R, Farrell M, Degenhardt L. Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis. JAMA Psychiatry. 2021;78(9):979\u201393. https:\/\/doi.org\/10.1001\/jamapsychiatry.2021.0976.","journal-title":"JAMA Psychiatry"},{"key":"628_CR6","doi-asserted-by":"publisher","DOI":"10.17226\/25310","volume-title":"Engineering, and Medicine. Medications for opioid use disorder save lives","author":"National Academies of Sciences","year":"2019","unstructured":"National Academies of Sciences. Engineering, and Medicine. Medications for opioid use disorder save lives. Washington, DC: National Academies; 2019. https:\/\/doi.org\/10.17226\/25310."},{"issue":"1","key":"628_CR7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1172\/JCI134708","volume":"130","author":"ND Volkow","year":"2020","unstructured":"Volkow ND, Blanco C. Medications for opioid use disorders: clinical and pharmacological considerations. J Clin Investig. 2020;130(1):10\u20133. https:\/\/doi.org\/10.1172\/JCI134708.","journal-title":"J Clin Investig"},{"issue":"6","key":"628_CR8","doi-asserted-by":"publisher","first-page":"e196373","DOI":"10.1001\/jamanetworkopen.2019.6373","volume":"2","author":"RL Haffajee","year":"2019","unstructured":"Haffajee RL, Lin LA, Bohnert ASB, Goldstick JE. Characteristics of US counties with high opioid overdose mortality and low capacity to deliver medications for opioid use disorder. JAMA Netw Open. 2019;2(6):e196373. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.6373.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"628_CR9","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1080\/00952990.2019.1694536","volume":"46","author":"JJ Lister","year":"2020","unstructured":"Lister JJ, Weaver A, Ellis JD, Himle JA, Ledgerwood DM. A systematic review of rural-specific barriers to medication treatment for opioid use disorder in the United States. Am J Drug Alcohol Abus. 2020;46(3):273\u201388. https:\/\/doi.org\/10.1080\/00952990.2019.1694536.","journal-title":"Am J Drug Alcohol Abus"},{"issue":"1","key":"628_CR10","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/jrh.12307","volume":"35","author":"CHA Andrilla","year":"2019","unstructured":"Andrilla CHA, Moore TE, Patterson DG, Larson EH. Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: a 5-year update. J Rural Health. 2019;35(1):108\u201312. https:\/\/doi.org\/10.1111\/jrh.12307.","journal-title":"J Rural Health"},{"issue":"1","key":"628_CR11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/jrh.12569","volume":"38","author":"CHA Andrilla","year":"2022","unstructured":"Andrilla CHA, Patterson DG. Tracking the geographic distribution and growth of clinicians with a DEA waiver to prescribe buprenorphine to treat opioid use disorder. J Rural Health. 2022;38(1):87\u201392. https:\/\/doi.org\/10.1111\/jrh.12569.","journal-title":"J Rural Health"},{"issue":"7","key":"628_CR12","doi-asserted-by":"publisher","first-page":"e231982","DOI":"10.1001\/jamahealthforum.2023.1982","volume":"4","author":"CM Jones","year":"2023","unstructured":"Jones CM, Olsen Y, Ali MM, Sherry TB, Mcaninch J, Creedon T, et al. Characteristics and prescribing patterns of clinicians waivered to prescribe buprenorphine for opioid use disorder before and after release of new practice guidelines. JAMA Health Forum. 2023;4(7):e231982. https:\/\/doi.org\/10.1001\/jamahealthforum.2023.1982.","journal-title":"JAMA Health Forum"},{"issue":"11","key":"628_CR13","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1001\/jama.2016.10542","volume":"316","author":"BD Stein","year":"2016","unstructured":"Stein BD, Sorbero M, Dick AW, Pacula RL, Burns RM, Gordon AJ. Physician capacity to treat opioid use disorder with buprenorphine-assisted treatment. JAMA. 2016;316(11):1211\u20132. https:\/\/doi.org\/10.1001\/jama.2016.10542.","journal-title":"JAMA"},{"issue":"1","key":"628_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13011-020-00312-3","volume":"15","author":"RL Haffajee","year":"2020","unstructured":"Haffajee RL, Andraka-Christou B, Attermann J, Cupito A, Buche J, Beck AJ. A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder. Subst Abuse Treat Prev Policy. 2020;15(1):69. https:\/\/doi.org\/10.1186\/s13011-020-00312-3.","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"4","key":"628_CR15","doi-asserted-by":"publisher","first-page":"e227028","DOI":"10.1001\/jamanetworkopen.2022.7028","volume":"5","author":"PJ Joudrey","year":"2022","unstructured":"Joudrey PJ, Kolak M, Lin Q, Paykin S, Anguiano JRV, Wang EA. Assessment of community-level vulnerability and access to medications for opioid use disorder. JAMA Netw Open. 2022;5(4):e227028. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.7028.","journal-title":"JAMA Netw Open"},{"key":"628_CR16","unstructured":"Consolidated A, Act H, R.2617. 2023. https:\/\/www.congress.gov\/bill\/117th-congress\/house-bill\/2617"},{"key":"628_CR17","unstructured":"HRSA. Defining rural population. HHS; 2024. https:\/\/www.hrsa.gov\/rural-health\/about-us\/what-is-rural"},{"key":"628_CR18","unstructured":"U.S. Census Bureau. American Community Survey 5-Year data (2009\u20132021): 2016\u20132020 estimates; 2022. https:\/\/www.census.gov\/data\/developers\/data-sets\/acs-5year.html"},{"key":"628_CR19","unstructured":"Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: Results from the 2020 National Survey on Drug Use and Health (HHS Publication No. PEP21-07-01-003, NSDUH, Series H-. 56). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2021. Retrieved from https:\/\/www.samhsa.gov\/data\/"},{"key":"628_CR20","unstructured":"Center for Behavioral Health Statistics and Quality (CBHSQ). Results from the 2020 National Survey on Drug Use and Health: Detailed tables. Rockville, MD: Substance Abuse and Mental Health Services Administration (SAMHSA). 2021. Retrieved from https:\/\/www.samhsa.gov\/data\/"},{"issue":"8","key":"628_CR21","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1176\/appi.ps.202000529","volume":"72","author":"B Franz","year":"2021","unstructured":"Franz B, Dhanani LY, Miller WC. Rural-urban differences in physician bias toward patients with opioid use disorder. Psychiatr Serv. 2021;72(8):874\u20139.","journal-title":"Psychiatr Serv"},{"key":"628_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13011-021-00417-3","volume":"16","author":"L Garpenhag","year":"2021","unstructured":"Garpenhag L, Dahlman D. Perceived healthcare stigma among patients in opioid substitution treatment: a qualitative study. Subst Abuse Treat Prev Policy. 2021;16:1\u201312.","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"628_CR23","doi-asserted-by":"publisher","first-page":"100138","DOI":"10.1016\/j.dadr.2023.100138","volume":"6","author":"A Carl","year":"2023","unstructured":"Carl A, Pasman E, Broman MJ, Lister JJ, Agius E, Resko SM. Experiences of healthcare and substance use treatment provider-based stigma among patients receiving methadone. Drug Alcohol Depend Rep. 2023;6:100138.","journal-title":"Drug Alcohol Depend Rep"},{"key":"628_CR24","doi-asserted-by":"publisher","first-page":"209270","DOI":"10.1016\/j.josat.2023.209270","volume":"159","author":"K McLean","year":"2024","unstructured":"McLean K, Murphy J, Kruis N. I think we\u2019re getting better but we\u2019re still not there: provider-based stigma and perceived barriers to care for people who use opioids (PWUO). J Subst Use Addict Treat. 2024;159:209270.","journal-title":"J Subst Use Addict Treat"},{"issue":"2","key":"628_CR25","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/ACM.0000000000005467","volume":"99","author":"E Magnan","year":"2024","unstructured":"Magnan E, Weyrich M, Miller M, Melnikow J, Moulin A, Servis M, Henry SG. Stigma against patients with substance use disorders among health care professionals and trainees and stigma-reducing interventions: a systematic review. Acad Med. 2024;99(2):221\u20132.","journal-title":"Acad Med"},{"issue":"6","key":"628_CR26","doi-asserted-by":"publisher","first-page":"S208","DOI":"10.1016\/j.amepre.2018.02.006","volume":"54","author":"CHA Andrilla","year":"2018","unstructured":"Andrilla CHA, Coulthard C, Patterson DG. Prescribing practices of rural physicians waivered to prescribe buprenorphine. Am J Prev Med. 2018;54(6):S208\u201314.","journal-title":"Am J Prev Med"},{"issue":"1","key":"628_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13722-021-00282-2","volume":"17","author":"KP Conway","year":"2022","unstructured":"Conway KP, Khoury D, Hilscher R, Aldridge AP, Parker SJ, Zarkin GA. Rural and urban differences in undersupply of buprenorphine provider availability in the United States, 2018. Addict Sci Clin Pract. 2022;17(1):1\u20135.","journal-title":"Addict Sci Clin Pract"},{"key":"628_CR28","doi-asserted-by":"publisher","first-page":"102704","DOI":"10.1016\/j.drugpo.2020.102704","volume":"85","author":"EL Richard","year":"2020","unstructured":"Richard EL, Schalkoff CA, Piscalko HM, et al. You are not clean until you\u2019re not on anything: perceptions of medication-assisted treatment in rural Appalachia. Int J Drug Policy. 2020;85:102704.","journal-title":"Int J Drug Policy"},{"issue":"14","key":"628_CR29","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1080\/10826084.2021.1975749","volume":"56","author":"EF Madden","year":"2021","unstructured":"Madden EF, Prevedel S, Light T, Sulzer SH. Intervention stigma toward medications for opioid use disorder: a systematic review. Subst Use Misuse. 2021;56(14):2181\u2013201.","journal-title":"Subst Use Misuse"},{"issue":"1","key":"628_CR30","doi-asserted-by":"publisher","first-page":"2399316","DOI":"10.1080\/07853890.2024.2399316","volume":"56","author":"H Piscalko","year":"2024","unstructured":"Piscalko H, Dhanani LY, Brook D, Hall OT, Miller WC, Go V, Franz B. Knowledge of medications for opioid use disorder and associated stigma among primary care professionals. Ann Med. 2024;56(1):2399316.","journal-title":"Ann Med"},{"issue":"21","key":"628_CR31","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1001\/jama.2021.4469","volume":"325","author":"BD Stein","year":"2021","unstructured":"Stein BD, Saloner B, Schuler MS, Gurvey J, Sorbero M, Gordon AJ. Concentration of patient care among buprenorphine-prescribing clinicians in the US. JAMA. 2021;325(21):2206\u20138. https:\/\/doi.org\/10.1001\/jama.2021.4469.","journal-title":"JAMA"},{"key":"628_CR32","volume-title":"Laying the foundation for HRSA\u2019s RCORP initiative: findings from RCORP\u2019s first implementation cohort","author":"C Mun","year":"2023","unstructured":"Mun C, Zambrano R, Tallman E, Schuler H, Waibel E, Heller G, Payne RK, Meyers K. Laying the foundation for HRSA\u2019s RCORP initiative: findings from RCORP\u2019s first implementation cohort. Report prepared for the Health Resources and Services Administration. North Bethesda, MD: JBS International, Inc; 2023."},{"key":"628_CR33","unstructured":"Tallman E, Mun C, Zambrano R, Schuler H, Waibel E, Heller G, Mueller D, Payne RK, Meyers K. Laying the foundation for HRSA\u2019s RCORP initiative: findings from RCORP\u2019s medication-assisted treatment-expansion (MAT-E) cohort. Report prepared for the Health Resources and Services Administration. JBS International, Inc; 2023."},{"key":"628_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102701","author":"HL Cooper","year":"2020","unstructured":"Cooper HL, Cloud DH, Freeman PR, Fadanelli M, Green T, Van Meter C, et al. Buprenorphine dispensing in an epicenter of the U.S. opioid epidemic: a case study of the rural risk environment in Appalachian Kentucky. Int J Drug Policy. 2020;85:102701. https:\/\/doi.org\/10.1016\/j.drugpo.2020.102701","journal-title":"Int J Drug Policy"},{"key":"628_CR35","doi-asserted-by":"crossref","unstructured":"Kazerouni NJ, Irwin AN, Levander XA, Geddes J, Johnston K, Gostanian CJ et al. Pharmacy-related buprenorphine access barriers: an audit of pharmacies in counties with a high opioid overdose burden. Drug Alcohol Depend. 2021;224:108729.","DOI":"10.1016\/j.drugalcdep.2021.108729"},{"issue":"1","key":"628_CR36","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.japh.2019.06.016","volume":"60","author":"T Thakur","year":"2020","unstructured":"Thakur T, Frey M, Chewning B. Pharmacist roles, training, and perceived barriers in naloxone dispensing: a systematic review. J Am Pharmacists Association: JAPhA. 2020;60(1):178\u201394. https:\/\/doi.org\/10.1016\/j.japh.2019.06.016.","journal-title":"J Am Pharmacists Association: JAPhA"},{"key":"628_CR37","unstructured":"HHS Buprenorphine Practice Guidelines Evaluation Workgroup. Early changes in waivered clinicians and utilization of buprenorphine for opioid use disorder after implementation of the 2021 HHS buprenorphine practice guidelines. U.S. Department of Health and Human Services Assistant Secretary for Planning and Evaluation (ASPE). 2022. Accessed from: https:\/\/aspe.hhs.gov\/sites\/default\/files\/documents\/ed38939a27154d27d87f2543f7de4cfa\/buprenorphine-practice-guideline-early-impacts.pdf"},{"key":"628_CR38","doi-asserted-by":"publisher","unstructured":"Haffajee RL, Bohnert ASB, Lagisetty PA. (2018). Policy pathways to address provider workforce barriers to buprenorphine treatment. American Journal of Preventive Medicine. 2018;54(6 Suppl 3); 230\u2013S242. https:\/\/doi.org\/10.1016\/j.amepre.2017.12.022","DOI":"10.1016\/j.amepre.2017.12.022"},{"key":"628_CR39","unstructured":"Substance Abuse and Mental Health Services Administration. Publication No. PEP23-02-01-001. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2023. Incorporating Peer Support Into Substance Use Disorder Treatment Services. Treatment Improvement Protocol (TIP) Series 64."},{"key":"628_CR40","unstructured":"U.S. Department of Agriculture Economic Research Service. Rural Classifications, Overview; 2024. https:\/\/www.ers.usda.gov\/topics\/rural-economy-population\/rural-classifications\/"},{"issue":"10","key":"628_CR41","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1111\/add.15458","volume":"116","author":"P Reuter","year":"2021","unstructured":"Reuter P, Caulkins JP, Midgette G. Heroin use cannot be measured adequately with a general population survey. Addiction. 2021;116(10):2600\u20139.","journal-title":"Addiction"},{"key":"628_CR42","volume-title":"Dual public health emergenhows: How rural RCORP communities are responding to COVID-19 and the opioid epidemic Report prepared for the Hresourcesourceservicesrvices Administration","author":"E Regalbuto","year":"2021","unstructured":"Regalbuto E, Schachtner R, Schuler HR, Kuritzky A, Rupp S, Birmingham C, Bresani E, Mun C, Tate E, Meyers K. Dual public health emergencies: How rural RCORP communities are responding to COVID-19 and the opioid epidemic. Report prepared for the Health Resources and Services Administration. North Bethesda, MD: JBS International, Inc; 2021."}],"container-title":["Substance Abuse Treatment, Prevention, and Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-024-00628-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13011-024-00628-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-024-00628-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T13:07:13Z","timestamp":1734700033000},"score":1,"resource":{"primary":{"URL":"https:\/\/substanceabusepolicy.biomedcentral.com\/articles\/10.1186\/s13011-024-00628-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,20]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["628"],"URL":"https:\/\/doi.org\/10.1186\/s13011-024-00628-4","relation":{"references":[{"id-type":"uri","id":"","asserted-by":"subject"}]},"ISSN":["1747-597X"],"issn-type":[{"value":"1747-597X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,20]]},"assertion":[{"value":"4 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was deemed exempt by JBS\u2019 institutional review board given that data were part of required grant reporting.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Data availability.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"47"}}